Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Inclusion Criteria:

• Participants with Diagnostic and Statistical Manual of Mental Disorders, FifthEdition Text Revision (DSM-5-TR) primary diagnosis of schizophrenia or bipolar Idisorder, or autism spectrum disorder as confirmed by Kiddie Schedule for AffectiveDisorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) at the Screening Visit 1 (for de novo subjects, or as previouslyconfirmed in parent study for subjects who completed Study 3112-301-001 or M21-465).

• De novo participants must have normal physical examination findings, clinicallaboratory test results, and electrocardiogram (ECG) results at Screening Visit 1.Abnormal results must not be clinically significant as determined by theinvestigator. Participants enrolling after completion of Study M21-465 or 3112-301-001 have had monitoring of laboratory tests, physical examinations, andECGs at the completion visit of the parent studies.

• Participant must have a caregiver (parent or legally authorized representative) whois willing and able to be responsible for safety monitoring of the participant,provide information about the participant's condition, oversee administration ofstudy intervention, and accompany the participant to all study visits.

Exclusion Criteria:

• Participants with DSM-5-TR diagnosis of major depressive disorder, schizoaffectivedisorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorderdue to another medical condition. Participants with ASD that is associated with Rettdisorder, fragile-X syndrome, or childhood disintegrative disorder.

• Prior DSM-5-TR diagnosis of intellectual disability (IQ < 70) for schizophrenia andbipolar I disorder participants. Prior DSM-5-TR diagnosis of profound intellectualdisability (IQ < 25) for ASD participants.

• Participant has a condition or is in a situation, which, in the investigator'sopinion, may put the participant at significant risk, may confound the studyresults, or may interfere significantly with the participant's participation in thestudy.